Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Infectious Diseases

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1086/527329PMID 18266603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hunter's Tropical Medicine and Emerging Infectious Diseases

  2019cited by this paper
• Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.

  2008cited by this paper
• Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).

  2007cited by this paper
• Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.

  2006cited by this paper
• Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

  2006cited by this paper
• Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes.

  2005cited by this paper
• Recombination and flavivirus vaccines: a commentary.

  2005cited by this paper
• Live flavivirus vaccines: reasons for caution.

  2004cited by this paper
• Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

  2004cited by this paper
• Activation of the cytokine network and unfavorable outcome in patients with yellow fever.

  2004cited by this paper
• Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay.

  2003cited by this paper
• The extent of homologous recombination in members of the genus Flavivirus.

  2003cited by this paper
• Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4.

  1998cited by this paper
• Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

  1992cited by this paper
• Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1

  1986cited by this paper

• Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination

  2024cites this paper
• Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.

  2023cites this paper
• Dengue Virus: Infection, Immunological Response, and Vaccine Development

  2021cites this paper
• No evidence for sylvatic cycles of chikungunya, dengue and Zika viruses in African green monkeys (Chlorocebus aethiops sabaeus) on St. Kitts, West Indies

  2020cites this paper
• A review of Dengvaxia®: development to deployment

  2019cites this paper
• Vaccination Against Dengue: Challenges and Current Developments.

  2016cites this paper
• Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains

  2016cites this paper
• The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells

  2016cites this paper
• Breakthrough: Nobel Prize Discoveries in Viral Pathogenesis

  2016cites this paper
• Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy.

  2015cites this paper
• Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

  2015cites this paper
• Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Epitopes Identification for Vaccine Design and Structural Aspects of Dengue Virus 3 Envelope Protein

  2014cites this paper
• Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.

  2014cites this paper
• ive virus vaccines based on a yellow fever vaccine backbone : tandardized template with key considerations for a risk / benefit

  2014cites this paper
• Identification and characterization of the genetic determinants for yellow fever virus infection and dissemination in Aedes aegypti

  2014cites this paper
• A Chimeric Dengue Virus Vaccine using Japanese Encephalitis Virus Vaccine Strain SA14-14-2 as Backbone Is Immunogenic and Protective against Either Parental Virus in Mice and Nonhuman Primates

  2013cites this paper
• Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2

  2013cites this paper
• Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus

  2013cites this paper
• Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

  2012cites this paper
• Fragment-Based Molecular Design of New Competitive Dengue Den2 Ns2b/Ns3 Inhibitors from the Components of Fingerroot (Boesenbergia rotunda)

  2012cites this paper
• Serologic Reactivity to Leptospira and Dengue virus of Febrile Patients from Guayaquil Slums.

  2012cites this paper
• Classical Live Viral Vaccines

  2011cites this paper
• Dengue virus protease inhibitors

  2011cites this paper
• Stability of Yellow Fever Virus under Recombinatory Pressure as Compared with Chikungunya Virus

  2011cites this paper
• Recombinant, Chimeric, Live, Attenuated Vaccines Against Flaviviruses and Alphaviruses

  2011influential citation
• Vaccination of travelers: how far have we come and where are we going?

  2011cites this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cites this paper
• Desenvolvimento de uma vacina tetravalente contra dengue* Development of Sanofi Pasteur tetravalent dengue vaccine Desarrollo de una vacuna tetravalente contra dengue

  2011cites this paper
• Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

  2010cites this paper
• Development of sanofi pasteur tetravalent dengue vaccine

  2010cites this paper
• Report of an NIAID workshop on dengue animal models.

  2010cites this paper
• IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine

  2010cites this paper
• Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.

  2010cites this paper
• Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development

  2010cites this paper
• Bioinformatics in New Generation Flavivirus Vaccines

  2010cites this paper
• Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.

  2010cites this paper
• Recent progress on sanofi pasteur's dengue vaccine candidate.

  2009cites this paper
• Pathogenesis and prevention of dengue virus infection: state-of-the-art

  2009cites this paper
• Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: A potential model for vaccine testing

  2009cites this paper
• Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.

  2008cites this paper
• Safety concerns with regard to live attenuated flavivirus vaccines.

  2008cites this paper
• Polymorphism of the Staphylococcus aureus Panton-Valentine leukocidin genes and its possible link with the fitness of community-associated methicillin-resistant S. aureus.

  2008cites this paper
• Dengue vaccines for travelers

  2008cites this paper
• Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781].

  2008cites this paper